Surgalign Holdings ($SRGA) $2.075M SEC Fair Fund

Late claims are being considered for compensation, subject to approval.

$2,075,000

Cash Settlement

SEC

Court

3-20945

Case number

04/23/2015

Class period Start

03/16/2020

Class period End

02/23/2026

Claim deadline

Surgalign Holdings ($SRGA) has agreed to pay $2.075 million through an SEC Fair Fund to investors, resolving claims related to its failure to disclose the financial risks associated with aggressive sales tactics.

Outline

Between 2015 and 2019, Surgalign boosted reported sales by shipping products early, often without customer approval, to meet revenue targets. This practice made revenue growth appear stronger than it was. However, in 2020, the company restated its financials to correct this situation. The SEC later found violations of GAAP and internal control failures. Surgalign and former CFO Robert Jordheim settled, and a $2.075 million Fair Fund was established for investors.

Timeline
Between 2015 and 2019: Surgalign routinely shipped orders early—sometimes without customer approval—to boost revenue recognition.
On March 16, 2020: The company disclosed an internal investigation into revenue recognition practices.
On June 8, 2020: Surgalign issued a restatement covering fiscal years 2016 to 2018 and parts of 2014, 2015, and 2019.
On August 3, 2022: The SEC announced a settlement with Surgalign and former CFO Robert Jordheim, including a $2.075M civil penalty to fund investor compensation.
In January, 2026: The court set February 23, 2026, as the deadline to submit claims for the settlement.
Background

Surgalign Holdings, formerly known as RTI Surgical Holdings, Inc., was once marketed to investors as a resilient player in the medical technology sector. Between 2015 and 2019, the company’s leadership highlighted its ability to consistently meet revenue guidance and achieve financial targets.

However, the SEC later found that Surgalign was meeting these targets through an undisclosed practice of "pulling sales forward" from future quarters. 

Basically, the company frequently shipped orders weeks or even months before customers had actually requested delivery.

This tactic allowed Surgalign to prematurely recognize revenue in violation of Generally Accepted Accounting Principles (GAAP). By shifting future sales into current periods, the company addressed projected revenue shortfalls while keeping investors in the dark about the mounting uncertainty of its future income.

On March 16, 2020, Surgalign issued a press release announcing an internal investigation into its revenue recognition practices. The probe focused on how the company handled contractual arrangements with original equipment manufacturers.

Following the announcement, the stock price plunged more than 27% over the next two trading days, falling from $2.75 to $1.99.

On the next days when news of the SEC inquiry broke, shares fell over 14% to close at $2.35.

By June 2020, Surgalign was forced to restate financial data for every fiscal year from 2014 through 2018, as well as several quarters in 2019.

And, in the end, the SEC concluded that the company’s apparent success was a result of accounting misconduct, leading to a $2.075 million penalty to fund investor compensation.

What Can Investors Expect Now?

Surgalign Holdings ($SRGA) has agreed to pay $2.075 million through an SEC Fair Fund to investors, resolving claims related to its failure to disclose the financial risks associated with aggressive sales tactics.

If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section below.

Case Type

SEC Fair Fund

Case Status

Accepting Late Claims

Alleged Offence

Misleading Statements,

Financial Misrepresentation

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Administrator

EPIQ

Trades matching type

FIFO

Frequently Asked Questions

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.